[an error occurred while processing this directive] | [an error occurred while processing this directive]
Current treatment of recurrent nasopharngeal carcinoma
He Meilin, Yi Junlin
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Science and Peking Union Medical College,Beijing 100021,China
Abstract On the basis of intensity-modulated radiotherapy (IMRT)-based comprehensive treatment, the 5-year overall survival rate of initially-treated nasopharngeal carcinoma patients without recurrence and metastasis has reached 80%, local regional control rate has exceeded 90%,whereas approximately 10%-15% of patients will suffer from local and/or nodal recurrence after initial treatment. The factors affecting the decision-making of re-treatment mainly include the causes of local and/or nodal recurrence of nasopharngeal carcinoma after initial treatment, selection of re-treatment, side effects and efficacy after re-treatment. This article summarizes the recent progress on these issues above.
[1] Chen YP, Chan ATC, Le QT, et al. Nasopharyngeal carcinoma[J]. Lancet, 2019, 394(10192):64-80. DOI:10.1016/s0140-6736(19)30956-0.
[2] Sun X, Su S, Chen C, et al. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma:an analysis of survival and treatment toxicities[J]. Radiother Oncol, 2014, 110(3):398-403. DOI:10.1016/j.radonc.2013.10.020.
[3] 中国抗癌协会鼻咽癌专业委员会,林少俊,陈晓钟,等. 复发鼻咽癌治疗专家共识[J]. 中华放射肿瘤学杂志, 2018, 27(1):16-22. DOI:10.3760/cma.j.issn.1004-4221.2018.01.004.
Nasopharynx Cancer Professional Committee of China Anti-Cancer Association, Lin SJ, Chen XZ, et al. Expert consensus on the treatment of recurrent NPC[J]. Chin J Radiat Oncol, 2018, 27(1):16-22. DOI:10.3760/ cma.j.issn.1004-4221.2018.01.004.
[4] 钟毓,黎静. 复发鼻咽癌的治疗研究进展[J]. 医疗卫生装备,2009, 30(7):37-40. DOI:10.3969/j.issn.1003-8868.2009.07.012.
Zhong Y, Li J. Therapeutic progression of recurrent nasopharyngeal carcinoma[J]. Chin Med Equip J, 2009, 30(7):37-40. DOI:10.3969/j.issn.1003-8868.2009.07.012.
[5] 李金高,陈晓钟,林少俊,等. 鼻咽癌复发、转移诊断专家共识[J]. 中华放射肿瘤学杂志,2018, 27(1):7-15. DOI:10.3760/cma.j.issn.1004-4221.2018.01.002.
Li JG, Chen XZ. Expert consensus on the diagnosis of recurrent or metastatic nasopharyngeal carcinoma[J]. Chin J Radiat Oncol, 2018,27(1):7-15. DOI:10.3760/cma.j.issn.1004-4221.2018.01.002.
[6] Zhao W, Lei H, Zhu X, et al. Investigation of long-term survival outcomes and failure patterns of patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy:a retrospective analysis[J]. Oncotarget, 2016, 7(52):86914-86925. DOI:10.18632/oncotarget.13564.
[7] Fisch UP. Cervical lymph flow in man following radiation and surgery[J]. Trans Am Acad Ophthalmol Otolaryngol, 1965, 69(5):846-868.
[8] Lin DS, Jen YM, Lee JC, et al. Recurrence of nasopharyngeal carcinoma in the parotid region after parotid-gland-sparing radiotherapy[J]. J Formos Med Assoc, 2011, 110(10):655-660. DOI:10.1016/j.jfma.2011.08.009.
[9] 邸小青,胡新荣. 鼻咽癌放疗后复发的分子机理研究进展[J]. 西南军医,2009, 11(5):936-939. DOI:10.3969/j.issn.1672-7193.2009.05.085.
Di XQ, Hu XR. Therapeutic progression of recurrent nasopharyngeal carcinoma[J]. J Mili Surg Southwest China, 2009, 11(5):936-939. DOI:10.3969/j.issn.1672-7193.2009.05.085.
[10] Kang M, Zhou PT, Li GS, et al. Validation of the8th edition of the UICC/AJCC staging system for nasopharyngeal carcinoma treated with intensity-modulated radiotherapy[J]. Oncotarget, 2017, 8(41):70586-70594. DOI:10.18632/oncotarget.19829.
[11] Pan JJ, Ng WT, Zong JF, et al. Prognostic nomogram for refining the prognostication of the proposed8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy[J]. Cancer, 2016, 122(21):3307-3315. DOI:10.1002/cncr.30198.
[12] 周明,徐昕. 鼻咽癌首程放疗后 578例颈部淋巴结复发因素分析[J]. 肿瘤学杂志,2004, 10(5):367-368. DOI:10.3969/j.issn.1671-170X.2004.05.030.
Zhou M, Xu X. Analysis of the factors associated with cervical lymph node recurrence after primary radiotherapy in 578 cases with nasopharyngeal carcinoma[J]. J Oncol, 2004, 10(5):367-368. DOI:10.3969/j.issn.1671-170X.2004.05.030.
[13] 林灿峰,李东升,林柏翰,等. 鼻咽癌治疗后局部复发回顾性研究[J]. 中华肿瘤防治杂志,2017, 24(3):188-191. DOI:10.16073/j.cnki.cjcpt.2017.03.009.
Lin CF, Li DS, Lin BH, et al. Distant metastasis of nasopharyngeal carcinoma after treatment:A 15-year follow-up study[J]. Chin J Cancer Prevent Treat, 2017, 24(3):188-191. DOI:10.16073/j.cnki.cjcpt.2017.03.009.
[14] 张攀,张迪,戴晓波. 复发鼻咽癌再程放射治疗的研究进展[J]. 实用肿瘤学杂志, 2019, 33(1):92-96. DOI:10.11904/j.issn.1002-3070.2019.01.017.
Zhang P, Zhang D, Dai XB. Advanced in re-radiotherapy for recurrent nasopharyngeal carcinoma[J]. Pract Oncol J, 2019, 33(1):92-96. DOI:10.11904/j.issn.1002-3070.2019.01.017.
[15] Na'ara S, Amit M, Billan S, et al. Outcome of patients undergoing salvage surgery for recurrent nasopharyngeal carcinoma:a meta-analysis[J]. Ann Surg Oncol, 2014, 21(9):3056-3062. DOI:10.1245/s10434-014-3683-9.
[16] Liu J, Yu H, Sun X, et al. Salvage endoscopic nasopharyngectomy for local recurrent or residual nasopharyngeal carcinoma:a 10-year experience[J]. Int J Clin Oncol, 2017, 22(5):834-842. DOI:10.1007/s10147-017-1143-9.
[17] 陈明远,郭翔,文卫平,等. 局限性残留、复发鼻咽癌的鼻内镜进路救援性外科治疗[J]. 癌症, 2007, 26(7):673-678. DOI:10.3321/j.issn.1000-467X.2007.07.001.
Chen MY, Guo X, Wen WP, et al. Salvage surgical operation via endoscopic transnasal approach for local persistent or recurrent nasopharyngeal carcinoma[J]. Chin J Cancer, 2007, 26(7):673-678. DOI:10.3321/j.issn.1000-467X.2007.07.001.
[18] You R, Zou X, Hua YJ, et al. Salvage endoscopic nasopharyngectomy is superior to intensity-modulated radiation therapy for local recurrence of selected T1-T3 nasopharyngeal carcinoma-A case-matched comparison[J]. Radiother Oncol, 2015, 115(3):399-406. DOI:10.1016/j.radonc.2015.04.024.
[19] Weng J, Wei J, Si J, et al. Clinical outcomes of residual or recurrent nasopharyngeal carcinoma treated with endoscopic nasopharyngectomy plus chemoradiotherapy or with chemoradiotherapy alone:a retrospective study[J]. PeerJ, 2017, 5:e3912. DOI:10.7717/peerj.3912.
[20] 唐秋,胡巧英. 鼻咽癌放疗后颈淋巴结复发再治疗临床分析[J]. 中国肿瘤临床,2010, 37(1):13-15. DOI:10.3969/j.issn.1000-8179.2010.01.004.
Tang Q, Hu QY. Analysis of re-treatment for cervical lymph node recurrence in nasopharyngeal carcinoma patients after radiotherapy[J]. Chin J Clin Oncol, 2010, 37(1):13-15. DOI:10.3969/j.issn.1000-8179.2010.01.004.
[21] You R, Zou X, Wang SL, et al. New surgical staging system for patients with recurrent nasopharyngeal carcinoma based on the AJCC/UICC rTNM classification system[J]. Eur J Cancer, 2015, 51(13):1771-1779. DOI:10.1016/j.ejca.2015.05.014.
[22] Han F, Zhao C, Huang SM, et al. Long-term outcomes and prognostic factors of re-irradiation for locally recurrent nasopharyngeal carcinoma using intensity-modulated radiotherapy[J]. Clin Oncol (R Coll Radiol), 2012, 24(8):569-576. DOI:10.1016/j.clon.2011.11.010.
[23] Karam I, Huang SH, McNiven A, et al. Outcomes after reirradiation for recurrent nasopharyngeal carcinoma:North American experience[J]. Head Neck, 2016, 38(Suppl 1):E1102-1109. DOI:10.1002/hed.24166.
[24] Kong L, Wang L, Shen C, et al. Salvage intensity-modulated radiation therapy (IMRT) for locally recurrent nasopharyngeal cancer after definitive imrt:a novel scenario of the modern era[J]. Sci Rep, 2016, 6:32883. DOI:10.1038/srep32883.
[25] Lee AW, Foo W, Law SC, et al. Reirradiation for recurrent nasopharyngeal carcinoma:factors affecting the therapeutic ratio and ways for improvement[J]. Int J Radiat Oncol Biol Phys, 1997, 38(1):43-52. DOI:10.1016/s0360-3016(97)00244-7.
[26] 周珺珺, 应红梅, 胡超苏, 等. 复发鼻咽癌调强放疗的应用疗效及预后分析[J]. 中国癌症杂志, 2012,(11):835-841. DOI:10.3969/j.issn.1007-3969.2012.11.007.
Zhou JJ, Ying HM, Hu CS, et al. Efficacy and prognosis of intensity modulated radiotherapy for recurrent nasopharyngeal carcinoma[J]. China Oncol, 2012, 22(11):835-841. DOI:10.3969/j.issn.1007-3969.2012.11.007.
[27] 张慧慧,张献文,江浩. 局部复发鼻咽癌再程调强放射治疗的疗效及预后分析[J]. 上海交通大学学报(医学版), 2018, 38(6):662-669. DOI:10.3969/j.issn.1674-8115.2018.06.014?.
Zhang HH, Zhang XW, Jiang H. Clinical efficacy and prognostic factors of locally recurrent nasopharyngeal carcinoma with intensity-modulated radiotherapy[J]. J Shanghai Jiaotong Univ (Med Sci), 2018, 38(6):662-669. DOI:10.3969/j.issn.1674-8115.2018.06.014?.
[28] Tian YM, Zhao C, Guo Y, et al. Effect of total dose and fraction size on survival of patients with locally recurrent nasopharyngeal carcinoma treated with intensity-modulated radiotherapy:a phase 2, single-center, randomized controlled trial[J]. Cancer, 2014, 120(22):3502-3509. DOI:10.1002/cncr.28934.
[29] Lee VH, Kwong DL, Leung TW, et al. Hyperfractionation compared to standard fractionation in intensity-modulated radiation therapy for patients with locally advanced recurrent nasopharyngeal carcinoma[J]. Eur Arch Otorhinolaryngol, 2017, 274(2):1067-1078. DOI:10.1007/s00405-016-4339-0.
[30] Tian YM, Tian YH, Zeng L, et al. Prognostic model for survival of local recurrent nasopharyngeal carcinoma with intensity-modulated radiotherapy[J]. Br J Cancer, 2014, 110(2):297-303. DOI:10.1038/bjc.2013.715.
[31] Tian YM, Guan Y, Xiao WW, et al. Long-term survival and late complications in intensity-modulated radiotherapy of locally recurrent T1 to T2 nasopharyngeal carcinoma[J]. Head Neck, 2016, 38(2):225-231. DOI:10.1002/hed.23880.
[32] Tian YM, Huang WZ, Yuan X, et al. The challenge in treating locally recurrent T3-4 nasopharyngeal carcinoma:the survival benefit and severe late toxicities of re-irradiation with intensity-modulated radiotherapy[J]. Oncotarget, 2017, 8(26):43450-43457. DOI:10.18632/oncotarget.15896.
[33] Leong YH, Soon YY, Lee KM, et al. Long-term outcomes after reirradiation in nasopharyngeal carcinoma with intensity-modulated radiotherapy:a meta-analysis[J]. Head Neck, 2018, 40(3):622-631. DOI:10.1002/hed.24993.
[34] 唐天兰,徐鹭英,潘建基,等.69例复发鼻咽癌近距离超分割放疗远期疗效分析[J]. 中国癌症杂志,2011, 21(3):201-206. DOI:10.3969/j.issn.1007-3969.2011.03.009.
Tang TL, Xu LY, Pan JJ, et al. Long-term efficacy of hyperfractionated intracavitary brachytherapy on 69 patients with locally recurrent nasopharyngeal carcinoma[J]. China Oncol, 2011, 21(3):201-206. DOI:10.3969/j.issn.1007-3969.2011.03.009.
[35] Cheah SK, Lau FN, Yusof M, et al. Treatment outcome with brachytherapy for recurrent nasopharyngeal carcinoma[J]. Asian Pac J Cancer Prev, 2014, 14(11):6513-6518. DOI:10.7314/apjcp.2013.14.11.6513.
[36] Kong L, Gao J, Hu JY, et al. Phase Ⅰ/Ⅱ trial evaluating concurrent carbon-ion radiotherapy plus chemotherapy for salvage treatment of locally recurrent nasopharyngeal carcinoma[J]. Chin J Cancer, 2016, 35(1):101. DOI:10.1186/s40880-016-0164-5.
[37] 胡集祎,高晶,胡微煦,等. 碳离子治疗IMRT后局部区域复发鼻咽癌初步研究——上海市质子重离子医院临床经验[J]. 中华放射肿瘤学杂志,2020, 29(3):161-165. DOI:10.3760/cma.j.issn.1004-4221.2020.03.001.
Hu JY, Gao J, Hu WX, et al. Preliminary study of intensity-modulated carbon ion reirradiation for locoregionally recurrent nasopharyngeal carcinoma after definitive IMRT——Clinical experience from Shanghai Proton Heavy Ion Hospital[J]. Chin J Radiat Oncol, 2020, 29(3):161-165. DOI:10.3760/cma.j.issn.1004-4221.2020.03.001.
[38] Liu SW, Li JM, Chang JY, et al. A treatment planning comparison between proton beam therapy and intensity-modulated x-ray therapy for recurrent nasopharyngeal carcinoma[J]. J Xray Sci Technol, 2010, 18(4):443-450. DOI:10.3233/xst-2010-0265.
[39] Zhang LL, Li YY, Hu J, et al. Proposal of a pretreatment nomogram for predicting local recurrence after intensity-modulated radiation therapy in t4 nasopharyngeal carcinoma:a retrospective review of 415 Chinese patients[J]. Cancer Res Treat, 2018, 50(4):1084-1095. DOI:10.4143/crt.2017.359.
[40] Guan Y, Liu S, Wang HY, et al. Long-term outcomes of a phase Ⅱ randomized controlled trial comparing intensity-modulated radiotherapy with or without weekly cisplatin for the treatment of locally recurrent nasopharyngeal carcinoma[J]. Chin J Cancer, 2016, 35:20. DOI:10.1186/s40880-016-0081-7.
[41] Zhang L, Huang Y, Hong S, et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma:a multicentre, randomised, open-label, phase 3 trial[J]. Lancet, 2016, 388(10054):1883-1892. DOI:10.1016/s0140-6736(16)31388-5.
[42] 李能平,黄瑞文,冯庆,等. 调强放疗联合吉西他滨加顺铂化疗治疗复发性鼻咽癌的近期疗效观察[J]. 肿瘤基础与临床,2017, 30(5):407-409. DOI:10.3969/j.issn.1673-5412.2017.05.012.
Li NP, Huang RW, Feng Q, et al. IMRT combined with gemcitabine plus cisplatin chemotherapy in the treatment of recurrent nasopharyngeal carcinoma[J]. J Basic Clin Oncol, 2017, 30(5):407-409. DOI:10.3969/j.issn.1673-5412.2017.05.012.
[43] Ng WT, Ngan RKC, Kwong DLW, et al. Prospective, Multicenter, phase 2 trial of induction chemotherapy followed by bio-chemoradiotherapy for locally advanced recurrent nasopharyngeal carcinoma[J]. Int J Radiat Oncol Biol Phys, 2018, 100(3):630-638. DOI:10.1016/j.ijrobp.2017.11.038
[44] 王承兴,李晓艳,顾焕华,等. EB病毒LMP1在鼻咽癌细胞系中上调EGFR表达[J]. 中华肿瘤杂志,2001, 23(4):269-272. DOI:10.3760/j.issn:0253-3766.2001.04.002.
Wang CX, Li XY, Gu HH. Increase in EGFR expression by Epstein-Barr virus LMP1 in nasopharyngeal carcinoma cells[J]. Chin J Oncol, 2001, 23(4):269-272. DOI:10.3760/j.issn:0253-3766.2001.04.002.
[45] Sigismund S, Avanzato D, Lanzetti L. Emerging functions of the EGFR in cancer[J]. Mol Oncol, 2018, 12(1):3-20. DOI:10.1002/1878-0261.12155.
[46] 叶奕菁,陆小军,吴新光,等. 表皮生长因子受体在鼻咽癌组织总的表达与临床意义[J]. 临床和实验医学杂志,2007, 6(4):85. DOI:10.3969/j.issn.1671-4695.2007.04.050.
Ye YJ, Lu XJ, Wu XG, et al. The expression and clinical significance of epidermal growth factor receptor in nasopharyngeal carcinoma[J]. J Clin Exp Med, 2007, 6(4):85. DOI:10.3969/j.issn.1671-4695.2007.04.050.
[47] 蒋骑,黄俊辉,胡冰. 尼妥珠单抗联合化疗治疗鼻咽癌临床观察[J]. 中国耳鼻咽喉颅底外科杂志,2014, 20(4):372-373. DOI:10.11798/j.issn.1007-1520.201404028.
Jiang J, Huang JH, Hu B, et al. Clinical observation of nimotuzumab combined with chemotherapy for nasopharyngeal carcinoma[J]. Chin J Otorhinolaryngol Skull Base Surg, 2014, 20(4):372-373. DOI:10.11798/j.issn.1007-1520.201404028.
[48] Chan AT, Hsu MM, Goh BC, et al. Multicenter, phase Ⅱ study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma[J]. J Clin Oncol, 2005, 23(15):3568-3576. DOI:10.1200/jco.2005.02.147.
[49] Almobarak AA, Jebreel AB, Abu-Zaid A. Molecular targeted therapy in the management of recurrent and metastatic nasopharyngeal carcinoma:a comprehensive literature review[J]. Cureus, 2019, 11(3):e4210. DOI:10.7759/cureus.4210.
[50] Ma BBY, Lim WT, Goh BC, et al. Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma:an international, multicenter study of the mayo clinic phase 2 consortium (NCI-9742)[J]. J Clin Oncol, 2018, 36(14):1412-1418. DOI:10.1200/jco.2017.77.0388.
[51] Wang F, Wei XL, Feng JF, et al. Recombinant humanized anti-PD-1 monoclonal antibody (JS001) in patients with refractory/metastatic nasopharyngeal carcinoma:Interim results of an open-label phase Ⅱ clinical study[J]. J Clin Oncol, 2019, 37(15 suppl):6017-6017. DOI:10.1200/JCO.2019.37.15_suppl.6017.
[52] Hsu C, Lee SH, Ejadi S, et al. Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma:results of the KEYNOTE-028 study[J]. J Clin Oncol, 2017, 35(36):4050-4056. DOI:10.1200/jco.2017.73.3675.
[53] Fang W, Yang Y, Ma Y, et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma:results from two single-arm, phase 1 trials[J]. Lancet Oncol, 2018, 19(10):1338-1350. DOI:10.1016/s1470-2045(18)30495-9.
[54] 李鹰飞,邱华平,龙剑,等. PD-1/PD-L1的表达与鼻咽癌患者临床分期及预后相关性研究[J]. 江西医药,2018, 53(6):573-574. DOI:10.3969/j.issn.1006-2238.2018.6.019.
Li YF, Qiu HP, Long J, et al. The relationship between the expression of PD-1/PD-L1 and clinical stage and prognosis of nasopharyngeal carcinoma patients[J]. Jiangxi Med J, 2018, 53(6):573-574. DOI:10.3969/j.issn.1006-2238.2018.6.019.
[55] Fang W, Zhang J, Hong S, et al. EBV-driven LMP1 and IFN-gamma up-regulate PD-L1 in nasopharyngeal carcinoma:Implications for oncotargeted therapy[J]. Oncotarget, 2014, 5(23):12189-12202. DOI:10.18632/oncotarget.2608.
[56] Finazzi T, Rordorf T, Ikenberg K, et al. Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy[J]. BMC Cancer, 2018, 18(1):395. DOI:10.1186/s12885-018-4295-8.
[57] Zhang J, Fang W, Qin T, et al. Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma[J]. Med Oncol, 2015, 32(3):86. DOI:10.1007/s12032-015-0501-6.
[58] Huang ZL, Liu S, Wang GN, et al. The prognostic significance of PD-L1 and PD-1 expression in patients with nasopharyngeal carcinoma:a systematic review and meta-analysis[J]. Cancer Cell Int, 2019, 19:141. DOI:10.1186/s12935-019-0863-5.
[59] Xiao M, Qi F, Chen X, et al. Functional polymorphism of cytotoxic T-lymphocyte antigen 4 and nasopharyngeal carcinoma susceptibility in a Chinese population[J]. Int J Immunogenet, 2010, 37(1):27-32. DOI:10.1111/j.1744-313X.2009.00888.x.
[60] Fang WF, Yang YP, Ma YX, et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma:results from two single-arm, phase 1 trials[J]. Lancet Oncol, 2018, 19(10):1338-1350. DOI:10.1016/s1470-2045(18)30495-9.
2021, Vol. 30 
